Umary Acido Hialuronico — Class I drug recall D-0620-2024
Ongoing recall by SoloVital, reported 2024-08-07, distributed nationwide. Marketed without an Approved NDA/ANDA: FDA analysis found product to be tainted with undeclared Diclofenac and
| Recall number | D-0620-2024 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | SoloVital, Chula Vista, CA, United States |
| Recall initiated | 2024-07-12 |
| Classified | 2024-07-29 |
| Reported by FDA | 2024-08-07 |
| Distributed | Nationwide (US) |
| Quantity | 1,331 bottles |
| Reason classes | undeclared allergen, unapproved product |
Product
Umary Acido Hialuronico, Suplemento Alimenticio, 850 mg caplets, packaged in 30-count bottles.
Reason for recall
Marketed without an Approved NDA/ANDA: FDA analysis found product to be tainted with undeclared Diclofenac and Omeprazole.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0620-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.